Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)

A laboratory rack holding multiple test tubes, each containing various colored liquids.

We are committed to advancing the understanding of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and pioneering new therapeutic options for this rare autoimmune disease.

Challenge

MOGAD is a rare autoimmune disease of the central nervous system that can affect people of all ages. It preferentially affects the optic nerve but can also affect the brain and spinal cord, causing severe and debilitating symptoms, including loss of vision, pain, fatigue, numbness, bladder/bowel or erectile dysfunction, impaired ambulation, and cognitive dysfunction.

The majority of people experience relapsing MOGAD, which is characterised by multiple, unpredictable attacks of worsening neurological symptoms. Symptoms may not fully resolve after an attack, leading to accumulating, permanent, neurological damage and disability. Treatments that prevent relapse and disability are needed to help people maintain their quality of life.

Focus

At Roche, we are working in partnership with the community to address the urgent needs of people living with MOGAD. Our focus is on advancing innovative research that addresses the underlying biology of the disease.

We are committed to applying our deep experience in neurology to the specific challenges of MOGAD. This commitment is driven by the goal of advancing the scientific understanding of the condition and exploring new avenues that can lead to future treatment options.